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ABSTRACT:
Human Germline Modification (HGM) involves the
alteration of genes in a human subject, thereby creating changes
to physical traits that can be passed on to the subject’s offspring.
Recent developments in genetic engineering, including the
discovery of the CRISPR/Cas9 gene editing tool, have made HGM
a realistic possibility in the near future. Currently, HGM in the
United States is regulated by a rider on the Appropriations Act
that prevents federal funding from being used for FDA review of
any treatment options involving HGM. The rider therefore
precludes the clinical development of any potential treatment that
utilizes HGM – even those designed to cure or prevent severe
inheritable diseases. This paper reviews the current state of the
science and law surrounding HGM, as well as the various ethical
principles that underlie current U.S. and international policy.
After careful consideration of these principles, this paper suggests
a middle path forward for the development of HGM in the near
future: an amendment to the current rider that allows the
development of HGM therapies to treat severe genetic diseases that
have no better alternative treatment.
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INTRODUCTION

Until recently, the prospect of altering the genetics of our
children has been speculative and remote, relegated to science
fiction and theoretical debate. However, with the advent of new
techniques in genetic engineering, mankind may soon have the
ability to introduce targeted mutations during in vitro
fertilization (IVF). These embryos may soon be implanted into a
womb, where they will develop into a baby and eventually be born
into this world: the first genetically engineered human beings in
history. No longer merely hypothetical, reproduction using
human germline modification (HGM)1 has become a pressing
international policy issue with serious implications for the future
of medicine.
This paper will begin by exploring various aspects of HGM
in its present state: (1) relevant advances in scientific
understanding and bioengineering technology; (2) the potential
clinical applications of HGM; and (3) the current international
and domestic landscape for regulation of HGM. In discussing
domestic HGM regulation, an emphasis is placed on the U.S. rider
on the 2016 Consolidated Appropriations Act that effectively
prevents the clinical development of HGM in the U.S.
Additionally, the legislative purpose of the rider will be discussed,
highlighting specific ethical concerns that have guided U.S.
policy.
Lastly, this paper will propose an amendment to the
current rider, which would allow the development of HGM as a
preventative therapy for severe genetic diseases. In making the
case for this amendment, this paper will explore three policy
options regarding the future of HGM for reproduction in the U.S.:
(1) failure to renew the rider for the following year; (2) renewal of
the rider in its intact form; and (3) adoption of the proposed
amendment to the current rider. Allowing the clinical
development of HGM for the treatment of severe monogenic
diseases may prevent unnecessary pain and suffering, reduce the
costs associated with these diseases, and ensure that the U.S.
remains an ethical and responsible leader in the field of
bioengineering.

Although HGM has potential research and development applications in many
biomedical fields, the exclusive focus of this paper is the use of HGM for
reproduction.
1
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BACKGROUND
A.

Genetic Diseases and Inheritance

Before discussing the potential applications of HGM, it is
critical to understand some of the basic science underlying
inherited diseases, which are typically caused by mutations in the
DNA that are passed from parent to offspring.2 Mutations in the
DNA may cause the production of defective proteins, which can
lead to genetic diseases.3 As opposed to the proteins encoded by
the wild-type gene4, these defective proteins either remain in the
cell, unable to properly function, or are detected by the cell and
destroyed.5 In either of these cases, the body is left unable to
perform a basic, yet highly important process, leading to the
symptoms of the disease.6 When a genetic disease is caused by
mutations in a single gene, they are known as monogenic
diseases, whereas those caused by the combined influence of
multiple genes are polygenic.7
Like physical traits, genetic diseases can be inheritable.8
This relationship is particularly evident in monogenic diseases.
For example, in an autosomal dominant disorder such as
Huntington’s disease, one chromosome carrying a mutated copy
of the gene is enough to cause the disease.9 In this case, if one
parent carries the mutation, there is a 50% chance of the child
being affected by the disease. In an autosomal recessive disorder,
both chromosomes must carry the afflicted gene. If both parents
carry the gene but are otherwise healthy, the child has a 25%
chance of being born with the disease. 10 For this reason,
See generally NEIL A. CAMPBELL & JANE B. REECE, BIOLOGY (Beth Wilbur et
al. eds., 7th ed. 2005).
3 See Campbell & Reece, supra note 2.
4 Wild-type genes are typically defined as the gene that encodes for the
phenotype that is the most common gene in a natural population. Here, it is
used to refer to any gene that codes for a phenotype that naturally occurs in a
substantial portion of the healthy population.
5 See Peter Bross, et al., Protein misfolding and degradation in genetic
diseases, 14 HUM. MUTATION 186 (Sep. 2, 1999), available at
http://www.els.net/WileyCDA/ElsArticle/refId-a0006016.html.
6 Id.
7 See generally Campbell & Reece, supra note 2.
8 See id.; see also U.S. Nat’l Library of Med., What are the different ways in
which a genetic condition can be inherited?, NIH GENETICS HOME REFERENCE
(Dec. 19, 2017),
https://ghr.nlm.nih.gov/primer/inheritance/inheritancepatterns [hereinafter
NIH Genetics].
9 See NIH Genetics, supra note 8.
10 Id.
2
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autosomal recessive diseases do not always present themselves in
every generation of a family.11 Diseases carried solely on the X or
Y sex chromosomes are known as X-linked12 and Y-linked13
diseases. In addition, some mitochondrial disorders are
inheritable genetic conditions caused by mutations in the
mitochondrial DNA.14
Although a monogenic disease is caused by a mutation in
only one gene, the resulting disease may still be complex.15 For
example, PKU is caused by a mutation that results in faulty PAH
enzymes, which metabolize the amino acid phenylalanine.16
However, symptoms of PKU are complex. They include heart
problems, small head, and low birth weight.17 Different mutations
on different parts of the gene can cause some symptoms of PKU
to be more severe than others.18 Additionally, the severity of these
symptoms are dependent on non-genetic, environmental factors,
such as a patient’s diet.19 Polygenic diseases are even more
complicated than monogenic diseases in both their symptoms and
inheritance patterns.20
B.
Clinical Applications of Genomic Screening
and Genetic Engineering
Generally speaking, there are three primary methods for
preventing inherited diseases at the stage of embryo formation
using advanced IVF techniques: (1) preimplantation genetic
diagnosis; (2) mitochondrial replacement therapy; and (3) human

Id.
See id. (explaining that X-linked diseases are caused by mutations in genes
on the X chromosome and can be also be both recessive and dominant. In Xlinked recessive diseases, the male children are more frequently affected
because they only carry one X chromosome).
13 Id.
14 See NIH Genetics, supra note 8.
15 See Charles R. Scriver & Paula J. Waters, Monogenic traits are not simple:
lessons from phenylketonuria, 15 TRENDS IN GENETICS 267, 267-70 (Jul.
1999), available at
http://www.sciencedirect.com/science/article/pii/S0168952599017618.
16 See id.
17 Id.
18 See Yoshiyuki Okano, et al., Molecular Basis of Phenotypic Heterogeneity in
Phenylketonuria, 324 N. ENGLAND J. MED. 1232 (May 2, 1991), available at
http://www.nejm.org/doi/full/10.1056/NEJM199105023241802#t=article.
19 See Charles R. Scriver, supra note 15.
20 See Kelly Frazer, et al., Human genetic variation and its contribution to
complex traits, 10 NATURE REV. GENETICS 241 (April, 2009), available at
http://www.nature.com/nrg/journal/v10/n4/full/nrg2554.html.
11
12
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germline engineering. The basics of these three methods are
discussed below.
1.

Pre-implantation Genetic Diagnosis

At the moment, some parents already attempt to avoid
inheritable diseases by using a technique called preimplantation
genetic diagnosis (PGD).21 PGD is accomplished by growing
several embryos during the IVF process, removing a cell from
each embryo or blastocyst, and sequencing each genome to assess
which embryos carry the inheritable disease.22 Those that do not
carry the disease are then implanted into the mother and brought
to term.23 This practice is widely employed in countries across the
world, including the U.S., to increase the chance that people
afflicted with genetic diseases will have healthy offspring.24
2.

Mitochondrial Replacement Therapy

When the mutated gene causing the disease is located on
the mitochondrial DNA (mtDNA) and not the nuclear DNA
(nDNA), mitochondrial replacement therapy (MRT) might be able
to prevent the passage of the disease to children.25 MRT is
predominantly accomplished using one of two techniques, both of
which involve the use of a donor’s mtDNA and the mother’s
nDNA.26 As the donor’s mtDNA does not carry the affected gene,
a child born from a successful MRT procedure should not develop
the disease.27 However, MRT may result in inheritable changes
See ASRM Ethics Committee, Use of preimplantation genetic diagnosis for
serious adult onset conditions: a committee opinion, 100 FERTILITY &
STERILITY 54 (Jul. 2013), available at
http://www.sciencedirect.com/science/article/pii/S0015028213003427.
22 See Joyce C. Harper & Sioban B. Sengupta, Prelimplantation genetic
diagnosis: State of the ART 2011, 131 HUMAN GENETICS 175 (Feb. 2012),
available at http://link.springer.com/article/10.1007/s00439-011-1056-z.
23 See id.
24 See id.
25 Klaus Reinhardt, et al., Mitochondrial Replacement, Evolution, and the
Clinic,
341
SCIENCE
1345
(Sep.
20,
2013),
available
at
http://science.sciencemag.org/content/341/6152/1345.full.
26 First, protonuclear spindle involves the transfer of nuclear DNA from a
fertilized zygote to an enucleated donor zygote. Alternatively, in maternal
spindle transfer, the nuclear material of an unfertilized oocyte can be
transferred to an enucleated donor oocyte. See P. Amato, et al., Three-parent
in vitro fertilization: gene replacement for the prevention of inherited
mitochondrial diseases, 101 FERTILITY & STERILITY 31, 32 (Jan. 2014),
available at https://www.ncbi.nlm.nih.gov/pubmed/24382342.
27 Reinhardt, et al., supra note 25.
21
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to DNA, particularly in female offspring.28 Because MRT has the
potential to create inheritable genetic changes, its use has been
controversial.29 Nevertheless, the United Kingdom has recently
become the first country to permit the clinical evaluation of
MRT.30
a.
Somatic Cell Engineering and Human
Germline Modification
There are two major clinical applications of gene editing:
somatic cell engineering (SCE) and human germline modification
(HGM). SCE typically entails editing copies of the affected gene
in the differentiated cells of an adult or child.31 In theory, the
patient’s germ cells are not affected during SCE, so the genetic
changes are not passed down to the next generation.32 Somatic
gene therapies are legal in the U.S., with many undergoing
clinical evaluation.33 The first somatic gene therapy achieved
market approval in the EU in 2012; however, commercial use has
thus far been limited.34
In reproductive HGM35 the DNA of either an embryo or
gametes is edited and the modified embryos or gametes are used
If the child is a female, she will pass the donor mtDNA to her progeny via
her eggs. While a male child would carry the donor’s mtDNA, it would not
pass the DNA down the germline because a father’s mtDNA is lost during
fertilization. See Anne Claiborne, et al. Mitochondrial Replacement
Techniques: Ethical, Social, and Policy Considerations, NAT’L ACADEMIES
PRESS, 6-7 (2016), available at
https://www.nap.edu/catalog/21871/mitochondrial-replacement-techniquesethical-social-and-policy-considerations.
29 See Robert Kiltzman, et al., Controversies concerning mitochondrial
replacement therapy, 103 FERTILITY & STERILITY 344-45 (Feb. 2015), available
at
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505924/pdf/nihms648296.pdf.
30 Ewen Callaway, UK moves closer to allowing ‘three-parent’ babies, NATURE
NEWS (Nov. 30, 2016), http://www.nature.com/news/uk-moves-closer-toallowing-three-parent-babies-1.21067.
31 W.F. Anderson, Prospects for human gene therapy, 226 SCIENCE 402 (Oct. 25,
1984), available at http://science.sciencemag.org/content/226/4673/401.
32 Id.
33 See Luigi Naldini, Gene therapy returns to centre stage, 526 NATURE 351
(Oct. 15, 2015), available at
http://www.nature.com/nature/journal/v526/n7573/full/nature15818.html.
34 See Antonio Regalado, The World’s Most Expensive Medicine Is a Bust, MIT
TECH. REV. (May 4, 2016), https://www.technologyreview.com/s/601165/theworlds-most-expensive-medicine-is-a-bust/.
35 For the purposes of this paper HGM refers to the reproductive use of
germline modification, not research on germline modifications that are done
28
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for reproduction via IVF.36 The edit is made at the earliest
possible stage of embryonic development; therefore, every cell of
the resulting person carries the edited gene, including the germ
cells.37 As a result, the altered gene will be propagated down the
germline to the offspring.38
b.
Therapy and Enhancement using
HGM
There are two general purposes for HGM treatment of
embryos: (1) the correction of genetic diseases to produce a
healthy child (therapy); and (2) the selection of specific desired
traits in an otherwise healthy child (enhancement).39 The use of
HGM for therapy would include the replacement of mutated
genes with their functional, wild-type counterparts.40 This can be
accomplished by deleting the former and inserting the latter, or
by directly editing the mutated genes, resulting in a functional
variant.41 Similarly, enhancement could be accomplished by
adding new genes, deleting unwanted genes, and editing existing
genes to create the desired phenotype.42 Both applications of
HGM would create heritable changes to the patient’s genome.
Accordingly, HGM has become extremely controversial and its

with no intention of implanting the embryo. Germline modification for
research, while exceedingly important, is beyond the scope of this paper.
36 See Tetsuya Ishii, Germline genome-editing research and its socioethical
implications, 21 TRENDS IN MOLECULAR MED. 473-80 (Aug. 2015), available at
http://www.cell.com/trends/molecular-medicine/pdf/S1471-4914(15)001070.pdf.
37 Id.
38 See, e.g., Pradeep Reddy, Selective Elimination of Mitochondrial Mutation in
the Germline by Genome Editing, 161 CELL 45 (Apr. 23, 2015), available at
http://www.cell.com/cell/abstract/S0092-8674(15)003712?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii
%2FS0092867415003712%3Fshowall%3Dtrue.
39 The distinction between therapy and enhancement is not always crystal
clear due to ambiguities in the meaning of “healthy” and “genetic diseases.”
For the purposes of this paper, “therapy” refers to the treatment of serious
genetic diseases that are caused by known genetic mutations and
“enhancement” refers to the selection of traits for non-therapeutic purposes,
including but not limited to selection of cosmetic features and the
augmentation of intellectual capacity.
40 See Naldini, supra note 33.
41 See Jeffry D. Sander & J. Keith Joung, CRISPR-Cas systems for editing,
regulating and targeting genomes, 32 NATURE BIOTECH. 347 (Jan. 31, 2014),
available at http://www.nature.com/nbt/journal/v32/n4/full/nbt.2842.html.
42 See id.
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use is heavily regulated or banned in many countries around the
world.43
C.
HGM Made Possible – CRISPR Genomic Editing
Technology
CRISPR, (Clustered Regularly Interspaced Short
Palindromic Repeats) is a gene-editing technique that has
revolutionized the field of genetic engineering.44 The
CRISPR/Cas9 system is composed of two parts: (1) the Cas9
nuclease, which is the enzyme responsible for cutting DNA,
allowing it to be edited; and (2) the guide RNA, which directs the
Cas9 nuclease to the target site by binding to the corresponding
sequence in the DNA.45 The CRISPR/Cas9 system is significantly
more efficient than previous gene editing methods.46 Using
automated RNA synthesis, new guide RNAs can be produced
quickly and cheaply, making it possible to target and edit
essentially any gene.47 The same nuclease can be used with two
or more guide RNAs to edit multiple genes simultaneously.48
Moreover, the Cas9 nuclease can be deactivated and combined
with different enzymes, allowing for additional site-specific
manipulation of DNA, including the conversion of a single
nucleotide to a different nucleotide,49 nucleotide deletions50 and
demethylation of target nucleotides.51 CRISPR’s modular
See Ishii, supra note 36.
See id.
45 See Martin Jinek, et al., A Programmable Dual-RNA-Guided DNA
Endonuclease in Adaptive Bacterial Immunity, 337 SCIENCE 816 (Aug. 17
2012), available at http://science.sciencemag.org/content/337/6096/816.full.
46 See, e.g., Prashant Mali, et al., RNA-Guided Human Genome Engineering
via Cas9, 339 SCIENCE 823, 825 (Feb. 15, 2013), available at
http://science.sciencemag.org/content/339/6121/823.long.
47 See Elizabeth Pennisi, The CRISPR Craze, 341 SCIENCE 833 (Aug. 23, 2013),
available at http://science.sciencemag.org/content/341/6148/833.
48 See, e.g., Le Cong, et al., Multiplex Genome Engineering Using CRISPR/Cas
Systems,
339
SCIENCE 6121
(Feb.
15,
2013),
available
at
http://science.sciencemag.org/content/339/6121/819.
49 See, e.g., Alexis C. Komor, et al., Programmable editing of a target base in
genomic DNA without double-stranded DNA cleavage, 533 NATURE 420, 42021 (May 19, 2016), available at
http://www.nature.com/nature/journal/v533/n7603/full/nature17946.html.
50 See, e.g., Keiji Nishida, et al., Targeted nucleotide editing using hybrid
prokaryotic and vertebrate adaptive immune systems, 353 SCIENCE 1248 (Aug
4, 2016), available at
http://science.sciencemag.org/content/early/2016/08/03/science.aaf8729.full.
51 See, e.g., Samrat Roy Choudury, et al., CRISPR-dCas9 mediated TET1
targeting for selective DNA demethylation at BRCA1 promotor, 7 ONCOTARGET
29
(Jun.
23,
2016),
available
at
43
44
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versatility, unprecedented accuracy, ease of use, and low cost
have opened the door to opportunities in genetic engineering that
were considered fiction less than ten years ago.
In the three years since Jennifer Doudna and Emmanuel
Charpentier’s landmark publication on CRISPR for gene editing,
research in the field has expanded at a breakneck pace. 52 The
technique has led to rapid advances in the development of
genetically-modified plants53 and customized animal models of
diseases.54 In 2014, scientists used CRISPR to edit two genes in
cynomolgus monkey embryos, leading to the birth of the first two
genetically-modified monkeys.55 Earlier this year, the National
Institutes of Health (NIH) approved a proposal for the clinical use
of the technology to edit human T-cells as part of a cancer
immunotherapy.56 Feng Zhang, MIT professor and CRISPR
pioneer, told the MIT Technology Review that the actual gene
editing of humans is only about “10 to 20 years away.”57
In fact, we may be much closer to HGM than anyone had
originally anticipated. Earlier this year, researchers at the
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&pa
ge=article&op=view&path%5B%5D=10234.
52 See Heidi Ledford, CRISPR: gene editing is just the beginning, 531 NATURE
NEWS (Mar. 7, 2016), http://www.nature.com/news/crispr-gene-editing-is-justthe-beginning-1.19510; Heidi Ledford, CRISPR, the disruptor, 522 NATURE
NEWS (Jun. 3, 2015), http://www.nature.com/news/crispr-the-disruptor1.17673; Addison V. Wright, et al., Biology and Applications of CRISPR
Systems: Harnessing Nature’s Toolbox for Genome Engineering, 164 CELL 29
(Jan.,
2016),
available
at
http://www.cell.com/cell/abstract/S00928674(15)01699-2.
53 See, e.g., Shigeo S. Sugano, et al., CRISPR/Cas9-mediated targeted
mutagenesis in the liverwort Marchantia polymorpha L., 55 PLANT & CELL
PHYSIOL.
475
(Jan.
18,
2014),
available
at
http://pcp.oxfordjournals.org/content/55/3/475.long.
54 See, e.g., Zhuchi Tu, et al. CRISPR/Cas9: a powerful genetic engineering tool
for establishing large animal models of neurodegenerative diseases, 10
MOLECULAR NEURODEGENERATION 35 (Aug. 4, 2015), available at
https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s130
24-015-0031-x.
55 See Yuyu Niu, et al., Generation of Gene-Modified Cynomolgus Monkey via
Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos, 156 CELL 836 (Feb.
13, 2014), available at http://www.cell.com/abstract/S0092-8674(14)00079-8;
see also Helen Shen, First monkeys with customized mutations born, NATURE
NEWS (Jan. 30, 2014), available at http://www.nature.com/news/first-monkeyswith-customized-mutations-born-1.14611.
56 Sara Reardon, First CRISPR clinical trial gets green light from US panel,
NATURE (Jun. 22, 2016), available at http://www.nature.com/news/first-crisprclinical-trial-gets-green-light-from-us-panel-1.20137.
57 See Antonio Regalado, Engineering the Perfect Baby, MIT TECH. REV. (Mar.
5, 2015), https://www.technologyreview.com/s/535661/engineering-the-perfectbaby/.
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Oregon Health and Science University utilized CRISPR/Cas9 to
achieve gene editing that resulted in viable human embryos.58
The researchers were able to correct mutations in the MYBPC3
gene that are responsible for hypertrophic cardiomyopathy, a
condition that leads to sudden death in young athletes.59 Gene
editing was successful in 42 out of 58 human embryos, with 41 of
these embryos containing two healthy, wild-type copies of the
MYBPC3 gene.60 Importantly, the techniques disclosed in this
report appeared to surpass two significant hurdles to utilizing
HGM by minimizing off-target gene edits and preventing
mosaicism of the embryos.61
Prior to this report, CRISPR had already been used to edit
human embryos. In 2015, the first report used CRISPR to alter
the hemoglobin gene (HBB) in non-viable zygotes.62 The authors
found that CRISRP/Cas9 system effectively cleaved the gene;
however, the inefficiency of repair process and gene incorporation
led to mosaicism of the embryo (embryos with cell-to-cell variation
in genes). 63 The authors also detected off-target cleavage,
indicating that the CRISPR/Cas9 system was not ready for
clinical application.64 In the second paper written prior to the
Oregon research, CRISPR was used on non-viable embryos to
introduce a naturally-occurring gene involved in HIV
resistance.65 Like the prior study, the authors found that the
CRISPR system was not efficient enough to consider clinical
applications.66 Although both of these studies used non-viable
embryos that could not develop into a fetus, the news of
engineered human embryos generated a significant amount of

Heidi Ledford, CRISPR fixes disease gene in viable human embryos, NATURE
NEWS (Aug. 2, 2017), available at http://www.nature.com/news/crispr-fixesdisease-gene-in-viable-human-embryos-1.22382.
59 Hong Ma, et al., Correction of a pathogenic gene mutation in human embryos,
548
NATURE
413-19
(Aug.
24,
2017),
available
at
http://www.nature.com/nature/journal/v548/n7668/full/nature23305.html.
60 Id. at 416.
61 Id.
62 Puping Liang, et al., CRISPR/Cas9-mediated gene editing in human
tripronuclear zygotes, 6 PROTEIN & CELL 363 (Apr. 1, 2015), available at
http://link.springer.com/article/10.1007/s13238-015-0153-5.
63 Id.
64 Id.
65 Xiangjin Kang, et al., Introducing precise genetic modifications into human
3PN embryos by CRISPR/Cas-mediated editing, 33 J. ASSIST. REPROD.
GENET. 581-88 (Apr. 6, 2016), available at
https://link.springer.com/article/10.1007%2Fs10815-016-0710-8.
66 Id.
58
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controversy.67 Scientists in the field have called for a voluntary
worldwide moratorium on any application of CRISPR to the
human germline.68 However, discussion is needed about the
potential risks and benefits of the various clinical applications of
CRISPR.
III. CURRENT LAWS REGULATING HGM IN THE UNITED
STATES
A.

FDA Jurisdiction over HGM

The FDA claims jurisdiction over HGM in the United
States.69 The FDA has jurisdiction over “drugs,”70 medical
“devices,”71 and “biological products.”72 In addition, it is the
primary agency tasked with the review of applications of gene
therapy.73 Thus, one likely source of the FDA’s jurisdiction over
HGM is that modified gametes or embryos may constitute
“biological products.”74 Alternatively, the FDA has the
jurisdiction to regulate the use of “human cells or tissues that are
intended for implantation . . . into a human,” which could include
the modified embryo.75 Some have challenged the scope of the
FDA’s authority to regulate procedures that utilize advanced

See, e.g., G. Burningham, We need to talk about human genetic engineering
before it’s too late, NEWSWEEK (Apr. 30, 2016),
http://www.newsweek.com/human-genome-editing-crispr-454315.
68 Antionio Regalado, Industry Body Calls for Gene-Editing Moratorium, MIT
TECH. REV. (Mar. 12, 2015),
https://www.technologyreview.com/s/535846/industry-body-calls-for-geneediting-moratorium/.
69 See Francis S. Collins, Statement on NIH funding of research using geneediting technologies in human embryos, U.S. DEP’T OF HEALTH & HUMAN
SERVICES: NIH (April 28, 2015), https://www.nih.gov/about-nih/who-weare/nih-director/statements/statement-nih-funding-research-using-geneediting-technologies-human-embryos.
70 21 U.S.C. § 321(g)(1).
71 21 U.S.C. § 321(h).
72 42 U.S.C. § 262(a).
73 See Application of Current Statutory Authorities to Human Somatic Cell
Therapy Products and Gene Therapy Products, 58 Fed. Reg. 53.248 (Oct. 14,
1993); see also Emily Marden & Dorothy Nelkin, Displaced Agendas: Current
Regulatory Strategies for Germline Gene Therapy, 45 MCGILL L.J. 461, 473-74
(2000).
74 See Elizabeth C. Price, Does the FDA have authority to regulate human
cloning?, 11 HARV. J. LAW & TECH 619 (1998) (discussing the possible statutory
basis for FDA authority over reproductive technologies, such as cloning).
75 See 21 C.F.R. § 1271.3.
67
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assisted reproduction technology (ART), such as cloning.76 While
it is interesting to consider the full scope of the FDA’s authority
to regulate HGM, such an analysis is beyond the scope of this
paper.
As a result of the FDA’s authority over HGM, premarket
approval and/or licensing would be required to market any
germline correction therapy.77 As a necessary step in the process,
an Investigational New Drug (IND) application must be filed with
the FDA and the procedure must be subjected to rigorous clinical
evaluation.78 It has been proposed that the FDA should apply an
additional level of scrutiny to HGM, ensuring safety for both the
children born from the process as well as any of those children’s
offspring.79 However, clinical investigation into the safety of HGM
is currently impossible in the U.S. under the existing legal
framework.80
B.

The 2017 Rider

Human germline modification is currently banned in the
United States, the result of a rider on the Consolidated
Appropriations Act of 2016 (2016 Act).81 The rider first appeared
in the House of Representatives’ draft of the Agriculture, Rural
Development, FDA and Related Agencies Appropriations Act of
2016.82 This draft was later incorporated into the 2016 Act, which
was signed into law on December 18, 2015.83 Located in Division
A, Title VII, section 749 of the 2016 Act, the rider reads as follows:

See Price, supra note 74; see also Marden, supra note 73 (briefly applying
Price’s analytical framework to FDA jurisdiction over HGM).
77 See 58 Fed. Reg. 53.248.
78 See 21 C.F.R. § 312.20 (requiring an IND application for both new drugs
under 21 U.S.C. 355(i) and biological products under 42 U.S.C. 262(a)(3)).
79 Niklaus H. Evitt, et al., Human Germline CRIPSR-Cas Modification:
Toward a Regulatory Framework, 15 AM. J. BIOETHICS 25 (Dec. 2, 2015),
available
at
http://www.tandfonline.com/doi/full/10.1080/15265161.2015.1104160.
80 See I. Glenn Cohen & Eli Y. Adashi, The FDA is prohibited from going
germline,
353
SCIENCE
545
(Aug.
5,
2016),
available
at
http://science.sciencemag.org/content/sci/353/6299/545.full.pdf.
81 Consolidated Appropriations Act, 2016, Pub. L. No. 114-13, 129 Stat. 2241,
2282 (2015).
82 Consolidated Appropriations Act of 2016, H.R. 2029, 114th Cong. (2015),
available at https://www.congress.gov/ bill/114th-congress/house-bill/2029
[hereinafter 2016 Act].
83 Id.
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None of the funds made available by this Act may
be used to notify a sponsor or otherwise acknowledge
receipt of a submission for an exemption for
investigational use of a drug or biological product
under section 505(i) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(i)) or section 351(a)(3)
of the Public Health Service Act (42 U.S.C. 262(a)(3))
in research in which a human embryo is
intentionally created or modified to include
a heritable
genetic modification.
Any
such
submission shall be deemed to have not been
received by the Secretary, and the exemption may
not go into effect.84
The rider remained in place as part of the Consolidated
Appropriations Act of 2017, located in Division A, Title VII, § 736
of the 2017 Act.85 This same rider is currently attached to the
Senate draft of the Agriculture, Rural Development, FDA and
Related Agencies Appropriations Act of 2018, which will likely
become part of the Consolidated Appropriations Act of 2018.86
Thus, there is a considerable chance that the effects of this rider
will perpetuate for at least another year.
C.

Effect of the Rider

The rider effectively prevents the FDA from evaluating the
safety and efficacy of any clinical therapy that requires a
heritable genetic modification of a human embryo.87 As any
treatment utilizing HGM necessarily results in a heritable
genetic modification, these treatments are prohibited by the
rider.88 The rider also has the effect of precluding the
development of MRT, which can result in an embryo with
Consolidated Appropriations Act, 2016, Pub. L. No. 114-13, § 749, 129 Stat.
2241, 2283 (2015).
85 Consolidated Appropriations Act, 2017, Pub. L. No. 115-31, § 736, 131 Stat.
135 (2017) [hereinafter 2017 rider].
86 The rider is now included as § 734 of the bill. See Making appropriations for
Agriculture, Rural Development, Food and Drug Administration, and Related
Agencies programs for the fiscal year ending September 30, 2018, and for other
purposes, S. 1603, 115th Cong. § 734 (as reported by S. Comm. on
Appropriations,
July
20,
2017),
available
at
https://www.congress.gov/bill/115th-congress/senate-bill/1603/text.
87 See Cohen & Adashi, supra note 80.
88 See Sara Reardon, US Congress moves to block human-embryo editing,
NATURE (Jun. 25, 2015), http://www.nature.com/news/us-congress-moves-toblock-human-embryo-editing-1.17858.
84
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alterations in its genome due to the incorporation of
mitochondrial DNA from the donor.89
This blanket prohibition on HGM and MRT is achieved by
blocking the FDA from reviewing or acknowledging the receipt of
an IND Application.90 An IND or application for marketing
approval can be obtained either by an application under section
505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §
355(i)) or section 351(a)(3) of the Public Health Service Act (42
U.S.C. § 262(a)(3)).91 By blocking both of these paths, the rider
effectively precludes the FDA review required to initiate a clinical
trial.
By precluding the FDA’s review of IND applications
through either the “new drug” or “biological product” routes, the
rider prevents scientists and clinicians from accurately assessing
the safety and efficacy of HGM therapies.92 Although not
technically a “ban” on HGM, the rider is sufficiently restrictive to
preclude the clinical-stage research that is required to obtain
either a new drug approval or a biological license.93 Without
either of these, anyone attempting to practice HGM in the U.S.
would be subject to severe civil penalties and/or criminal
sanctions.94 Thus, the rider is a complete and effective deterrent.
D.
Additional Sources of Regulating in the
United States
Although HGM is primarily regulated by the rider, there
are several additional layers of regulation that are relevant to
HGM. First, the NIH has some influence over the development of
HGM through its ability to appropriate funding.95 As opposed to
the FDA, the NIH does consider moral and ethical considerations

See Cohen & Adashi, supra note 80.
Id. (citing National Academies of Sciences, Engineering, and Medicine,
Mitochondrial Replacement Techniques: Ethical, Social, and Policy
Considerations (National Academies, Washington, DC, 2016)).
91 See 21 C.F.R. § 312.120 (2017).
92 See Cohen & Adashi, supra note 80.
93 See id.
94 See, e.g., 42 U.S.C. § 262(f) (2017) (violations of 42 U.S.C. § 262(a)(3) (2017)
are misdemeanors punishable by fines up to $500 and/or imprisonment up to
one year); 42 U.S.C. § 262(d)(2) (2017) (civil penalties of up to $100,000 per day
for biological products that are deemed by the Secretary to be a public health
hazard); 21 U.S.C. § 333(a) & 333(e) (2017) (violations of 21 U.S.C. § 355(i) may
be misdemeanors or felonies); 21 U.S.C. § 333(f) (2017) (civil penalties for
violations pertaining to medical devices).
95 Collins, supra note 69.
89
90
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when allocating its funds.96 Currently, federal funds may not be
used for research on HGM.97 The NIH guidelines indicate that
the institute “will not at present entertain proposals for germline
alteration,”98 precluding any NIH funding for this work.99
Second, the Dickey-Wicker Amendment (DWA) prohibits
federal funding for most embryonic research.100 Specifically, the
DWA prohibits the use of federal funds for: “(1) the creation of a
human embryo or embryos for research purposes; or (2) research
in which a human embryo or embryos are destroyed, discarded,
or knowingly subjected to risk of injury or death.”101 As the
clinical development of HGM would necessarily entail the
creation of human embryos for research purposes, the DWA
would prevent federal funds from being used to develop this
technology.102 However, these policies have no effect on the
legality of privately-funded research.103
IV.

INTERNATIONAL LAWS REGULATING HGM

The current status of international HGM regulation is a
mosaic of laws, guidelines, and recommendations.104 A study from
2014 found that 29 countries had a statutory ban on germline
editing. 105 However, in some of those countries with a statutory
See, e.g., Guiding Principles for Ethical Research, NAT’L INSTITUTES OF
HEALTH,
GUIDING
PRINCIPLES
FOR
ETHICAL
RESEARCH,
https://www.nih.gov/health-information/nih-clinical-research-trialsyou/guiding-principles-ethical-research.
97 Collins, supra note 69.
98 Id. at 51.
99 The Collins statement does not discuss the modification of human gametes
for research purposes. It is possible that such research may still be eligible for
NIH funding.
100 See Erik Parens & Lori P. Knowles, Reprogenetics and Public Policy:
Reflections and Recommendations, HASTINGS CTR. REP. S11, S13 (2003),
available
at
http://www.thehastingscenter.org/wpcontent/uploads/reprogenetics_and_public_policy.pdf.
101 Consolidated Appropriations Act, 2017, Pub. L. No. 115-31, § 508, 131 Stat.
135 (2017).
102 Collins, supra note 69.
103 See Parens & Knowles, supra note 100.
104 See Heidi Ledford, Where in the World Could the First CRISPR Baby be
Born?, 526 NATURE 310, 311 (Oct. 15, 2015), available at
http://www.nature.com/news/where-in-the-world-could-the-first-crispr-babybe-born-1.18542; see also Sara Reardon, Global summit reveals divergent views
on human gene editing, 528 NATURE 173 (Dec. 8, 2015), available at
http://www.nature.com/news/global-summit-reveals-divergent-views-onhuman-gene-editing-1.18971.
105 Motoko Araki & Tetsuya Ishii, International regulatory landscape and
integration of corrective genome editing into in vitro fertilization, 12 REPROD.
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ban, such as in Belgium, Bulgaria, Canada, and Sweden, there
may be ambiguity as to what is proscribed by these laws.106 For
example, it is ambiguous whether a germline correction that
resulted in a wild-type gene would actually be banned under the
laws of these countries.107 Moreover, the guidelines that ban
HGM in China, India, Ireland, and Japan may not be strictly
enforced.108 Of the legality of the procedure in ten other countries,
nine were also ambiguous.109 In the absence of a clear worldwide
consensus, this fluid patchwork of international regulation will
probably leave sufficient room for HGM research to continue
somewhere in the world.110 Two of the countries that may be most
likely to influence HGM regulation in the US are the United
Kingdom and China.
A.

The United Kingdom

The U.K. has one of the most comprehensive regulatory
systems in the world for assessing the scientific and medical
merits of new fertilization technology. In the United Kingdom,
IVF and other more advanced ART procedures are under the
regulation of the Human Fertilization and Embryology Authority
(HFEA).111 The HFEA is an independent regulatory body that
oversees research and fertility treatments that utilize gametes
and embryos.112 The HFEA was created in 1990 with the passage
of the Human Fertalisation and Embryology (HFE) Act of 1990,
which was recently amended in 2008.113
The U.K. is the most progressive country in the world with
respect to the use of MRT; in fact, clinics in the U.K. may begin
performing MRT as early as this year. The HFEA recently
announced that authorized clinics may apply to the HFEA for

BIOL.
ENDOCRINOL.
108,
(Nov.
24,
2014),
available
at
https://rbej.biomedcentral.com/articles/10.1186/1477-7827-12-108.
106 See Ishii, supra note 36.
107 Id.
108 Id.
109 Id.
110 Lauren F. Friedman, These are the countries where it’s ‘legal’ to edit human
embryos (hint: the US is one), BUSINESS INSIDER (Apr. 23, 2015, 2:15 PM),
http://www.businessinsider.com/china-edited-human-genome-laws-2015-4.
111
See
HUMAN
FERTILISATION
&
EMBRYOLOGY
AUTHORITY;
http://www.hfea.gov.uk (last visited Dec. 21, 2017).
112 See id.
113 See IVF the Law, HUMAN FERTILISATION & EMBRYOLOGY AUTHORITY (July
25, 2013),
http://hfeaarchive.uksouth.cloudapp.azure.com/www.hfea.gov.uk/134.html.
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license to treat patients using MRT.114 Parliament passed
regulations permitting the use of MRT in February 2015 and the
regulatory framework was put into place in October of 2016.115
However, the HFEA delayed their announcement until after they
received the official recommendations of the appointed expert
panel. The scientific panel recommended the use of MRT “as a
risk reduction treatment for carefully selected patients.”116 The
panel also recommended that the procedures be coupled with
prenatal testing and restricted to patients that do not have viable
alternatives, such as PGD.117
Obtaining authorization to treat a patient with MRT
requires a two-step process. First, a clinic must be reviewed by
the HFEA’s License Committee, who assess the clinic’s skill,
experience, and facilities.118 Next, the clinics must apply to the
Statutory Approvals Committee (SAC) for authorization to treat
any individual patient.119 After approval by both the HFEA and
the SAC, the clinics may perform MRT on the authorized patient
using either Maternal Spindle Transfer or Protonuclear Transfer
techniques.120
The regulation of HGM with CRISPR/Cas9 is far more
stringent than those governing MRT. As of early 2016, only one
molecular biologist, Kathy Niakan, has been granted permission
to perform gene editing in human embryos.121 However, the
embryo must be destroyed within 14 days and no embryo may be
implanted into a woman.122 Moreover, no research can be
undertaken without explicit approval from the HFEA ethics

See HFEA permits cautious use of mitochondrial donation in treatment,
following advice from scientific experts, HUMAN FERTILISATION &
EMBRYOLOGY AUTHORITY (Dec. 15, 2016),
http://hfeaarchive.uksouth.cloudapp.azure.com/www.hfea.gov.uk/10563.html.
115 Id.
116 See UK’s independent expert panel recommends “cautious adoption” of
mitochondrial donation in treatment, HUMAN FERTILISATION & EMBRYOLOGY
AUTHORITY (Dec. 15, 2016),
http://hfeaarchive.uksouth.cloudapp.azure.com/www.hfea.gov.uk/10559.html.
117 Id.
118 Id.
119 Id.
120 Id.
121 See HFEA approval for new “gene editing” techniques, FRANCIS CRICK
INSTITUTE
(Feb.
1,
2016),
https://www.crick.ac.uk/news/sciencenews/2016/02/01/hfea-decision/.
122 See Fiona MacDonald, 10 things you need to know about the UK allowing
genetic modification of human embryos, SCIENCE ALERT (Feb. 2, 2016),
http://www.sciencealert.com/10-things-you-need-to-know-about-the-uk-sdecision-to-allow-genetic-modification-of-human-embryos.
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committee.123 Although the use of HGM for reproduction is
prohibited in the U.K., their recent approval of MRT indicates
that the U.K. may be among the first nations to approve of
therapeutic applications of HGM.
B.

China

China was the first country to report the editing of the
human germline.124 Accordingly, the regulation of HGM in China
has become a hot topic of debate in the past two years.125 Many in
the West have accused the Chinese of being lackadaisical with
enforcement of regulations against HGM.126 However, others
argue that China’s ethical stance on the issue is not substantially
different than the United States or Europe.127 For example,
Chinese guidelines on HGM stipulate that “gene manipulation on
human game[te], zygote and embryo for the purpose of
reproduction is banned.”128
In China, HGM is regulated by a detailed regulatory
framework.129 Regulations promulgated by China’s Ministry of
Health130 include the Ethical Principles for ART and the Human
Sperm Bank of 2003, the Ethical Principles on ART of 2001, and
The Interim procedures for Human Genetic Resources
Management of 1998.131 The State Council has published a
preliminary draft of The Regulation of the Human Genetic
Resources, which will eventually replace the 1998 interim

Id.
See Liang, et al., supra note 62.
125 See, e.g., Sarah Knapton, China shocks world by genetically engineering
human embryos, THE TELEGRAPH (Apr. 23, 2015, 2:36 PM),
http://www.telegraph.co.uk/news/science/11558305/China-shocks-world-bygenetically-engineering-human-embryos.html; G. Owen Schaefer, China may
be the future of genetic enhancement, BBC FUTURE (Aug. 8, 2016),
http://www.bbc.com/future/story/20160804-china-may-be-the-future-ofgenetic-enhancement.
126 See, e.g., Rebecca Taylor, Mad Scientists in China Attempt to Create
Genetically-Modified Babies, It Didn’t Go Well, LIFENEWS.COM (Apr. 24, 2015),
http://www.lifenews.com/2015/04/24/mad-scientists-in-china-attempt-tocreate-genetically-modified-babies-it-didnt-go-well/.
127 See Xiaomei Zhai, et al., No ethical divide between china and the West in
human embryo research, 16 DEVELOPING WORLD BIOETHICS 116 (Jan. 21,
2016), available at http://onlinelibrary.wiley.com/doi/10.1111/dewb.12108/full.
128 Id. at 118.
129 See id.
130 The MoH is now known as the National Health and Family Planning
Commission. Id.
131 See Zhai, supra note 126, at 118 (and references therein).
123
124
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procedures.132 The net effect of these regulations is a system very
similar to those of many western countries, requiring informed
consent by participants and providing an absolute ban on the use
of HGM in reproduction.133 Nevertheless, the current law in
China amounts to non-binding guidelines and as a result,
development of HGM might continue in the future.134
V.

Statement of the Issue

The United States should amend the rider on the
Consolidated Appropriations Act of 2019 (2019 Act) to create an
exception to its current prohibition of HGM that would allow the
FDA to receive and review applications pertaining to the use of
HGM for the treatment of heritable monogenic diseases where the
edit would result in a wild-type gene. Such an exception would
provide a number of benefits, while minimizing the current safety
and ethical concerns surrounding HGM. Moreover, this would set
a precedent that would have a positive impact on the
international regulation of HGM, leading other countries to
seriously consider legalization and regulation. Although a similar
exception should also be made to facilitate the practice of MRT, a
full discussion of the policy implications leading to this suggestion
are beyond the scope of this paper.
VI.

ANALYSIS

Unless and until the United States is prepared to adopt a
formal legislative scheme to regulate HGM, there are three main
legislative options available: (1) completely remove the rider from
the 2019 Act; (2) leave the intact rider in place for the foreseeable
future; or (3) keep the rider in place and adopt a specific exception
or exceptions, such as those that would allow the FDA to receive
and review IND applications for the use of HGM to treat specific
monogenic diseases. The Author encourages the pursuit of the
third option for reasons that are discussed in the balance of this
article.
A.

Rationale Behind the Rider

Id.
Id.
134 See Ishii, supra note 36.
132
133
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The House of Representatives Committee Report, which
accompanied the 2016 Act, outlined the Congressional concerns
that led to the rider’s adoption:
The Committee understands the potential
benefits to society in the genetic modification of
living organisms. However, researchers do not yet
fully understand all the possible side effects of
editing the genes of a human embryo. Editing of the
human germ line may involve serious and
unquantifiable safety and ethical issues. Federal
and non-Federal organizations such as the National
Academy of Sciences and National Academy of
Medicine will soon engage in more extensive
scientific analysis of the potential risks of genome
editing and a broader public discussion of the
societal and ethical implications of this technique. In
accordance with the current policy at the National
Institutes of Health, the Committee includes bill
language that places a prohibition on the FDA’s use
of funds involving the genetic modification of a
human embryo. The Committee continues to support
a wide range of innovations in biomedical research,
but will do so in a fashion that reflects wellestablished scientific and ethical principles.135
From the text above, it is evident that the two predominant
Congressional concerns that led to the rider were those of safety
and ethics. Moreover, this passage indicates that future policies
on the subject must reflect “well-established scientific and ethical
principles.”136
Statements made during the hearing on “The Science and
Ethics of Genetically Engineered Human DNA” may shed some
light on these Congressional concerns.137 In the Statement of
Lamar Smith (R-TX), several points were raised.138 First, there is
See Report of the House Committee on Appropriations, Together with
minority
views
(to
accompany
H.R.
3049)
(2015),
https://www.congress.gov/114/crpt/ hrpt205/CRPT-114hrpt205.pdf.
136 Id.
137 The Science and Ethics of Genetically Engineered Human DNA: Hearing
Before the H. Comm. on Science, Space, and Technology, 114 Cong. 8-9 (2015)
(statement of Lamar Smith, Chairman of the Subcomm. on Research and
Technology), available at http://bit.ly/HouseSciCtte [hereinafter Lamar
Smith].
138 Id.
135
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a need “to prevent dangerous abuses and unintended
consequences” that might result from the inappropriate use of
this technology.139 Second, the U.S. should take the lead in the
scientific development and ethical application of genetic
engineering.140 Finally, our current technological understanding
of the CRISPR/Cas9 system needs to be refined so that patients
can be assured safe and ethical treatment.141
Some commenters contend that the major—if not only—
Congressional concern is that of ethics, not safety.142 For one, the
FDA already thoroughly investigates the safety of any procedure
during the IND application and subsequent clinical trials.143
Before any clinical trial commences, an applicant must prove that
the proposed drug is likely to be safe and effective by providing
data from extensive preclinical testing.144 During clinical
evaluation, the FDA requires standardized protocols,145 detailed
records,146 safety reports,147 and oversight by the Institutional
Review Board.148 Furthermore, if at any point during clinical
evaluation, the process does not appear safe, they may stop the
trial by placing it on “clinical hold.”149 Although inheritable
germline alterations may be unique insofar as they effect the
offspring of those who have undergone the therapy,150 the FDA
may already be well-suited to evaluate applications for
Id. at 8.
Id. (noting that “the United States can and should provide scientific and
moral leadership” in the field of HGM and “must take the lead in reviewing
new and innovative areas of science, such as genetically engineered DNA.”)
141 Id. (emphasizing the “need to better understand the technology and
procedures being used so that we can ensure patients are treated in the safest
and most ethical manner possible”).
142 See, e.g., Regalado, supra note 57 (quoting Professor Hank Greely as saying,
“I would not want to use safety as an excuse for a non-safety-based ban,” when
referring to the rider).
143 See generally U.S. DEPT. OF HEALTH & HUMAN SERV., SAFETY REPORTING
REQUIREMENTS FOR INDS AND BA/BE STUDIES: GUIDANCE FOR INDUSTRY AND
INVESTIGATORS
(2012),
available
at
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM227351.pdf.
144 Food & Drugs Act, 21 U.S.C. § 355(i)(1)(A) (2015) (requiring “the submission
to the Secretary before any clinical testing of a new drug is undertaken, of
reports . . . preclinical tests (including tests on animals) of such drug adequate
to justify the proposed clinical testing”).
145 21 C.F.R. § 312.23(a)(6) (2017).
146 21 C.F.R. §§ 312.57, 312.62, 312.64.
147 21 C.F.R. § 312.32.
148 21 C.F.R. § 312.66.
149 21 U.S.C. § 355(i)(3)(B)(i).
150 Edward Lanphier, et al., Don’t edit the human germ line, 519 NATURE 410,
410-11 (Mar. 26, 2015), available at http://www.nature.com/news/don-t-editthe-human-germ-line-1.17111.
139
140
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therapeutic HGM by applying enhanced scrutiny to its existing
IND procedure.151
While evaluation of safety is squarely within the FDA’s
jurisdiction, ethical or moral review is not.152 Congress has never
before used the FDA to enforce a prohibition on germline
modification.153 By precluding FDA review concerning the safety
and efficacy of any potential HGM applications, lawmakers have
demonstrated that they consider the ethical implications of HGM
to be the overriding concern. Interestingly, the rider was passed
only a few weeks after a summit, where the committee
highlighted the need to further evaluate the safety and ethics of
germline modification, discussed in greater detail below.154 It is
possible that the intention of the rider is to ensure a sound ethical
evaluation of HGM before proceeding to the assessment of its
safety.
These considerations of safety and ethics, as they apply to
each potential option, are considered below, with an emphasis on
relevant ethical issues. The potential effect of each policy on the
leadership of the U.S. in the field of HGM is also discussed.
B.

Evaluation of Potential Policy Options
1.

Refusal to Renew the Rider

Congress could refuse to renew the rider for the 2019 Act.
This would lift the ban on FDA receipt and review of any IND
applications for the use of HGM. Importantly, this would
potentially allow the clinical evaluation of HGM for both
therapeutic uses and non-therapeutic enhancement procedures.
Given the infancy of the technology, as well as the current
widespread disapproval of non-therapeutic applications of HGM,
failure to renew the rider is highly unlikely. Moreover, it may be
an ethically undesirable outcome that could lead to severe
unintended consequences for the industry.

Evitt, supra note 79.
See 21 U.S.C. § 301 et seq.; Fed. Reg. 53.248, supra note 73; PRESIDENT’S
COUNCIL ON BIOETHICS (U.S.), REPRODUCTION & RESPONSIBILITY: REPORT ON
THE REGULATION OF NEW BIOTECHNOLOGIES xii (2004), available at
https://repository.library.georgetown.edu/handle/10822/559381.
153 Cohen & Adashi, supra note 80.
154 Steve Olson, et al., International Summit on Human Gene Editing: A Global
Discussion, NAT’L ACAD. PRESS (Dec. 3, 2015), available at
http://nationalacademies.org/gene-editing/Gene-Edit-Summit/.
151
152
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Plausibility

Complete removal of the rider may not be popular given the
current status of public opinion concerning the propriety of
HGM.155 A recent Pew Research Center poll indicated that a
significantly portion of the U.S. public is worried about the
prospect of HGM (68%), and a much smaller population is
enthusiastic about the subject (49%).156 As the public is
significantly more adverse to the idea of genetic enhancements
than it is germline therapy, any policy that fails to draw a
distinction
between
therapeutic
and
non-therapeutic
enhancement is not likely to be received with public approval.157
Lack of public support among Congressional constituencies may
translate to less Congressional votes against renewing the rider.
Any attempt to repeal the rider in its entirety is
particularly unlikely to succeed because it would theoretically
enable FDA review of HGM for non-therapeutic enhancements.
The most zealous critiques of HGM pertain to its use in nontherapeutic enhancement and the possibility of eugenic
applications.158 Even among commenters who acknowledge the
potential utility of corrective germline therapy, many caution
against therapeutic use because of fears that it may lead to a
slippery slope resulting in non-therapeutic or eugenic
applications.159 Any action that opens up the possibility for
genetic enhancement is not likely to be well received.

Reardon, supra note 104.
Cary Funk, et al., U.S. Public Wary of Biomedical Technologies to ‘Enhance’
Human Abilities – 2. U.S. public opinion on the future use of gene editing, PEW
RES.
CTR.
REP.
(Jul.
26,
2016),
available
at
http://www.pewinternet.org/2016/07/26/u-s-public-opinion-on-the-future-useof-gene-editing/.
157 See id. (demonstrating that only 15% of adults believed enhancing
intelligence was an appropriate use for HGM, compared to 46% for reducing
the risk of serious diseases).
158 See, e.g., Robert Pollack, Eugenics lurk in the shadow of CRISPR, 348
SCIENCE 871 (May 22, 2015), available at
http://science.sciencemag.org/content/348/6237/871.1.
159 See, e.g., Nathaniel Comfort, Can We Cure Genetic Diseases Without
Slipping into Eugenics?, NATION (Jul. 16, 2015), available at
https://www.thenation.com/article/can-we-cure-genetic-diseases-withoutslipping-into-eugenics/; John Harris & Marcy Darnovsky, Pro and Con: Should
Gene Editing Be Performed on Human Embryos?, NAT’L GEOGRAPHIC (Aug.
2016),
http://www.nationalgeographic.com/magazine/2016/08/human-geneediting-pro-con-opinions/.
155
156

85

Striking a Balance: Policy Considerations for Human Germline Modification

b.

Safety and Ethical Implications

Nor is it necessarily desirable to permit the application of
HGM to non-therapeutic enhancement, as such application raises
significant ethical concerns. While supporters of HGM for
enhancement offer a variety of arguments in favor of the
practice,160 such practices raise deep-rooted concerns about the
close relationship between genetic enhancement and eugenics.161
The eugenics movement has been roundly criticized for promoting
a bigoted concept of genetic superiority based on race, class,
religious, and sexual prejudices.162 The American eugenic
movement led to the forced sterilization of over 64,000 people163
and may have contributed to the use of African-American men for
the Tuskegee study of untreated syphilis.164 Moreover, the
eugenic practices of Nazi Germany were modeled at least in part
by eugenics laws in U.S. states, particularly those in California.165
Given the potential social harm that could result from the eugenic
applications of HGM, use of this technology requires exceptionally
strong validation, which is lacking in the case of non-therapeutic
uses.
Some commentators have argued that the “new eugenics”
of the 20th Century is different than the “old eugenics” of historic
infamy and they highlight several distinctions between the
See, e.g., NICHOLAS AGAR, LIBERAL EUGENICS: IN DEFENSE OF HUMAN
ENHANCEMENT (2008) (arguing that that it is immoral to deprive parents of the
choice to enhance their children); Carl Shulman & Nick Bostrom, Embryo
Selection for Cognitive Enhancement: Curiosity or Game-changer?, 5 GLOBAL
POLICY
1,
85-92
(2014),
available
at
http://www.nickbostrom.com/papers/embryo.pdf (noting that that society could
be benefitted by enhanced individuals through innovation); John Harris, Why
human gene editing must not be stopped, GUARDIAN (Dec. 2, 2015),
https://www.theguardian.com/science/2015/dec/02/why-human-gene-editingmust-not-be-stopped.
161 See, e.g., Pollack, supra note 158; Anna Zaret, Editing Embryos: Considering
Restrictions on Genetically Engineering Humans, 67 HASTINGS L.J. 1805 (July
2016).
162 See Martin S. Pernick, Eugenics and Public Health in American History, 87
AMER. J. PUB. HEALTH 1767, 1770 (Nov. 1997), available at
http://ajph.aphapublications.org/doi/pdf/10.2105/AJPH.87.11.1767.
163 See Teryn Bouche & Laura Rivard, America’s Hidden History: The
Eugenics Movement, NATURE EDUC. (Sept. 18, 2014),
http://www.nature.com/scitable/forums/genetics-generation/america-s-hiddenhistory-the-eugenics-movement-123919444.
164 See Allan Brandt, Racism and Research: The Case of the Tuskegee Syphilis
Study, in SICKNESS AND HEALTH IN AMERICA, 331, 331-43 (Judith Leavitt &
Ronald Numbers eds., 2nd ed. 1985).
165 See EDWIN BLACK, WAR AGAINST THE WEAK: EUGENICS AND AMERICA’S
CAMPAIGN TO CREATE A MASTER RACE (2003).
160
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two.166 First, many of the tragedies of the old eugenic movement,
such as forced sterilizations of convicted criminals and people
with mental disabilities, were the result of government control.167
Enhancement applications of HGM would be guided by the
choices of individual parents, not government mandate, thereby
reducing the risk that such events would be repeated.168 Second,
society now has a more advanced understanding of the basic
biology of heredity than it did in the early 19th century.169
Opponents of this viewpoint argue this “new eugenics” of
genetic choice would lead to the same results as the “old
eugenics.”170 To begin with, there are several forces that may
undermine a parent’s autonomy in deciding to enhance their
children.171 In some situations, there may be community pressure
on a parent to obtain a specific enhancement for their child.172
Thus, the individual autonomy used to validate the “new
eugenics” may not be as clear of a distinction as its proponents
suggest.
There are also significant safety concerns that weigh
against the use of HGM for enhancement. Most importantly, the
traits that are most desirable to enhance are too complex to
achieve safe editing in human embryos, even if the technology
evolves to the point that prevention of monogenic diseases
becomes facile and safe. Traits such as height or intelligence are
controlled by potentially hundreds of genes.173 With every
additional edit, the chances of an off-target mutation grow
exponentially, increasing the probability of a serious adverse
See, e.g., A. Buchanan, Choosing Who Will Be Disabled: Genetic Intervention
and the Morality of Inclusion, 13 SOCIAL PHIL. & POLICY 18, 18-19 (1996); J.
HARRIS, ENHANCING EVOLUTION: THE ETHICAL CASE FOR MAKING BETTER
PEOPLE (2007).
167 See Eesha Pandit, America’s secret history of forced sterilization:
Remembering a disturbing and not-so-distant past, SALON (Jan. 29, 2106),
http://www.salon.com/2016/01/29/americas_secret_history_of_forced_sterilizat
ion_remembering_a_disturbing_and_not_so_distant_past/.
168 See Agar, supra note 160.
169 See Felipe E. Vizcarrondo, Human enhancement: The new eugenics, 81
LINACRE
Q.
239,
240
(Aug.
2014),
available
at
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135459/.
170 See Robert Sparrow, A Not-So-New Eugenics: Harris and Savulescu on
Human Enhancement, 41 HASTINGS CTR. REP. 32 (Jan. 2011), available at
http://onlinelibrary.wiley.com/doi/10.1002/j.1552146X.2011.tb00098.x/abstract?wol1URL=/doi/10.1002/j.1552146X.2011.tb00098.x/abstract&regionCode=US-CA&identityKey=7dcdcb83d981-423c-8aa4-fd9936536702.
171 Id. at 37-38.
172 Id. at 38-39.
173 See Frazer, supra note 20.
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event. With the technology still in its infancy, attempting such
experiments would constitute an unacceptable safety risk with a
high probability of treatment leading to an adverse event.
2.

Leaving the Rider Intact for Future Years

The second option is to leave the language of the current
rider intact for the 2019 Act. Absent significant lobbying effort on
behalf of the biotech industry, this may be the most likely outcome
for the foreseeable future. Similar riders have carried substantial
legislative inertia in the past, eventually becoming the “new
normal.” However, significant harm may result from such a
course because it may prevent the development of life-saving
therapies.
a.

Plausibility

Riders pertaining to reproductive choice have exhibited
striking longevity.174 For example, the DWA has been in effect for
twenty years.175 The DWA was originally attached to an
appropriations bill for the Department of Labor, Health and
Human Services and later became part of the Continuing
Resolution for Fiscal Year 1996.176 In addition, the Hyde
Amendment, which restricts the use of federal funds to pay for
abortion services, has been law for over four decades.177 The Hyde
Amendment was originally attached to the annual appropriations
bill in 1976.178 Both of these examples illustrate the fact that
riders governing reproductive health have considerable long-term
staying power. If a concerted effort is not made to change the
See Cohen & Adashi, supra note 80.
See Eli Y. Adashi & I. Glenn Cohen, Selective Regrets: The “Dickey
Amendments”
20
Years
Later,
JAMA
F.
(Nov.
5,
2015),
https://newsatjama.jama.com/2015/11/05/jama-forum-selective-regrets-thedickey-amendments-20-years-later/.
176 Id.
177 See Access Denied: Origins of the Hyde Amendment and other restrictions on
public funding for abortion, ACLU (last visited Dec. 21, 2017),
https://www.aclu.org/other/access-denied-origins-hyde-amendment-and-otherrestrictions-public-funding-abortion; see also Destiny Lopez, The Hyde
Amendment Has Been Hurting Women for 40 Years, But It’s Days Are
Numbered,
COSMOPOLITAN
(Sept.
23,
2016),
http://www.cosmopolitan.com/politics/a3621396/hyde-amendment.
178 See Marlene Gerber Fried, The Hyde Amendment: 30 Years of Violating
Women’s Rights, CENTER FOR AMERICAN PROGRESS (Oct. 6, 2006, 9:00 AM),
https://www.americanprogress.org/issues/women/news/2006/10/06/2243/thehyde-amendment-30-years-of-violating-womens-rights/.
174
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current rider, the blanket prohibition on HGM could continue for
decades to come.
b.

Safety and Ethical Implications

This path of least resistance is not without its own risks.
The longer the rider remains in place, the more difficult it may be
to repeal, as it becomes the “new normal.”179 If this broad
prohibition remains in place for too long, it may have the
unintended effects of (1) chilling important therapeutic research;
(2) causing the U.S. to forfeit its place as the world leader in the
scientific and ethical debate; and (3) preventing potential parents
from obtaining access to HGM for the treatment of debilitating
genetic diseases.
First, the rider may have the effect of chilling necessary
research and development on therapeutic gene editing in the U.S.
Long-term riders have already produced unfortunate
consequences for the scientific community.180 For example, the
DWA was present on the appropriations bill in 2009, which
President Obama signed just two days after lifting President
Bush’s executive order banning federal funding for stem cell
research.181 In 2010, the DWA was used to obtain a federal
injunction against federally-funded stem cell research that had
been approved by President Obama’s executive order.182 The
injunction was overturned the next year by the Court of Appeals
for the District of Columbia.183 Nevertheless, the uncertainty
caused by the temporary injunction disrupted the field of stem
See Cohen & Adashi, supra note 80; see also Eli Y. Adashi & I. Glenn Cohen,
Reproductive Freedom and the 2012 Presidential Election, JAMA F (Oct. 11,
2012),
https://newsatjama.jama.com/2012/10/11/jama-forum-reproductivefreedom-and-the-2012-presidential-election/.
180 Aaron D. Levine, Policy Uncertainty and the Conduct of Stem Cell Research,
8
CELL
STEM
CELL
132,
132
(Feb.
2011),
available
at
http://www.sciencedirect.com/science/article/pii/S1934590911000038; see also
Sarah Rodriguez, et al., An Obscure Rider Obstructing Science: The Conflation
of Parthenotes with Embryos in the Dickey-Wicker Amendment, 11 AMER. J.
BIOETHICS
20,
20-21
(Mar.
10,
2011),
available
at
http://www.tandfonline.com/doi/abs/10.1080/15265161.2010.546472.
181 Removing Barriers to Responsible Scientific Research Involving Human
Stem Cells, Executive Order 13505, 74 Fed. Reg. 10667 (Mar. 9, 2009),
available at http://edocket.access.gpo.gov/2009/pdf/E9-5441.pdf.; see also
Terrence P. Jeffery, Obama Signs Law Banning Federal Embryo Research Two
Days After Signing Executive Order to OK It, CNSNEWS.COM (Mar. 12, 2009,
5:04 PM), http://www.cnsnews.com/news/article/obama-signs-law-banningfederal-embryo-research-two-days-after-signing-executive-order.
182 Sherley v. Sebelius, 704 F. Supp. 2d 63 (D.D.C. 2010).
183 Sherley v. Sebelius, 644 F.3d 388 (D.C. Cir. 2011).
179
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cell research, leading to a chilling effect on research and the loss
of valuable resources.184 To avoid similar uncertainty in the policy
around HGM, it would be prudent to amend the current rider
before it leads to a similar result.
Second, the rider’s continued presence may prevent the
U.S. from “provid[ing] scientific and moral leadership” in the
field, thereby impeding another Congressional objective.185 Some
have already argued that the current regulatory framework puts
the U.S. at risk of falling behind in the development of gene
therapy.186 As of April 2016, experiments utilizing CRISPR/Cas9
on human embryos had either been approved or already
performed in China, Sweden, and the United Kingdom.187 More
experiments are likely to be approved in the near future, causing
the U.S. to lag behind in the research and development of HGM.
Falling behind on the scientific development of HGM in the long
term may negatively affect our legitimacy in the international
community, undermining our leadership role in important ethical
and scientific discussions.
Third and most importantly, failure to amend the rider
may prevent parents from having access to potentially life-saving
treatment, creating unnecessary suffering and increasing the
financial burden on the healthcare system. The WHO indicates
that “[t]he global prevalence of all single gene diseases at birth is
approximately 10/1,000.”188 It is estimated that monogenic
diseases affect up to 13 million people in the U.S., causing nearly
one-fifth of infant mortality.189 Many of the thousands of
monogenic diseases lead to severe physiological impairment or
early death.190 Prevention of these diseases using HGM could
prevent suffering for those afflicted as well as their family
members.
See Alla Katsnelson, US court suspends research on human embryonic
stem cells, NATURE (Aug. 25, 2010),
http://www.nature.com/news/2010/100824/full/news.2010.428.html.
185 Id.
186 Alex Pearlman, Scientists Argue the US Ban on Human Gene Editing Will
Leave It Behind, MOTHERBOARD (August 4, 2016, 11:02 AM),
http://motherboard.vice.com/read/scientists-argue-the-us-ban-on-humangene-editing-will-leave-it-behind.
187 Ewen Callaway, Gene-editing research in human embryos gains momentum,
532
NATURE
289,
289-90
(Apr.
19,
2016),
available
at
http://www.nature.com/news/gene-editing-research-in-human-embryos-gainsmomentum-1.19767.
188 Genomic resource centre: Genes and human disease, WORLD HEALTH ORG.,
http://www.who.int/genomics/public/geneticdiseases/en/index2.html
189 Id.
190 See id.
184
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Some proponents of the ban contend that the development
HGM is not necessary because alternative means would be
effective in a majority of cases.191 For example Eric Lander notes
that “it would be easier and safer simply to use PGD . . . in the
typical cases of a parent heterozygous for a dominant disease or
two parents who are carriers for a recessive disease.”192 Lander
concludes that situations that would necessitate HGM are
“vanishingly rare for most monogenic diseases.”193
Nevertheless, there are clearly situations in which HGM
might be required and in those cases, the real benefit to the
parents and children outweighs the speculative harm that drives
much of the opposition to HGM. For example, PGD would not be
sufficient when one parent is homozygous for an autosomal
dominant disease or both parents have a homozygous autosomalrecessive disease.194 Incidences of homozygosity have already
been documented in several deadly monogenic diseases, including
cystic fibrosis195 and Huntington’s disease.196 For these people,
the choices are clear: obtaining treatment using HGM, rearing a
sick child, or abstaining from procreation. Although these
situations may be rare, those inflicted are still human. Preventing
these people from receiving treatment should not be morally
justified by references to the speculative harm that may be
brought about by potential cosmetic applications of HGM.
3.
Amend the Rider to Include a Specific
Exception
The third option available to Congress is to amend the
rider, providing for specific exceptions for particular applications
Heidi Mertes & Guido Pennings, Modification of the Embryo’s Genome:
More Useful in Research Than in the Clinic, 15 AM. J. BIOETHICS 52, 53 (Dec.
2015), available at
http://www.tandfonline.com/doi/abs/10.1080/15265161.2015.1103813.
192 Eric S. Lander, Brave New Genome, 373 N. ENG. J. MED. 5, 7 (Jul. 2, 2015),
available at http://www.nejm.org/doi/full/10.1056/NEJMp1506446#t=article.
193 Id.
194 See Donald B. Kohn, et al., Ethical and regulatory aspects of genome editing,
126
BLOOD
2553,
2554
(Apr.
6,
2016),
available
at
http://www.bloodjournal.org/content/127/21/2553.abstract?sso-checked=true.
195 Vassos Neocleous, et al., Apparent homozygosity of p.Phe508del in CFTR
due to a large gene deletion of exons 4-11, 2014 CASE REP. GENET. 1, 2 (Feb. 6,
2014), available at https://www.hindawi.com/journals/crig/2014/613863/.
196 Ferdinando Squitieri, et al., Homozygosity for CAG mutation in
Huntington disease is associated with a more severe clinical course, 126 BRAIN
946, 946-47 (Apr. 1, 2003), available at
http://brain.oxfordjournals.org/content/brain/126/4/946.full.pdf.
191
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of HGM. For example, it would be sensible to allow the use of
HGM in the treatment of selected, well-studied monogenic
diseases. A specific exception for the use of HGM in monogenic
diseases would provide for the most ethically sound use of the
technology. Such an exception could help save human lives,
reduce the costs associated with genetic diseases, and protect the
reproductive freedom of individuals. Furthermore, these
exceptions would allow the scientific freedom that is necessary for
the U.S. to remain at the technical and ethical forefront of this
emerging technology. The author proposes one such exception.
The proposed amended rider reads as follows, where the
bold text indicates the amendment:
None of the funds made available by this Act may
be used to notify a sponsor or otherwise acknowledge
receipt of a submission for an exemption for
investigational use of a drug or biological product . .
. in which a human embryo is intentionally created
or
modified
to
include
a heritable
genetic modification, with the exception of a
submission pertaining to the treatment of
embryos where there is a substantial risk that
the child will be born with a severe or lifethreatening genetic disease,
where the
disease has a well-established and specific
genetic cause, where the modification results
in wild-type gene, and where the patients
could not obtain equally effective treatment
using other means. Any such submission shall be
deemed to have not been received by the Secretary,
and the exemption may not go into effect.197
a.

Plausibility

Amending the rider would not be unprecedented; riders
have been known to evolve over time. For example, the Hyde
Amendment initially provided a full ban on the use of federal
funds for abortion services.198 Since then, the Hyde Amendment

2017 rider, supra note 85 (text from the original rider has been preserved,
with the proposed amendment in bold for emphasis).
198 See ACLU, supra note 176.
197
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has been changed several times.199 In 1981, the amendment was
altered to include an exception “where the life of the mother would
be endangered if the fetus was carried to term.”200 It was changed
again in 1993, expanding federal funding to abortions related to
incidents of rape and incest.201 The first explicit call to repeal the
amendment was not until 2016.202
The proposed exception would reflect the differences in
public opinion between the use of HGM for therapy and its use for
enhancement. Polls indicate that people in the United States are
significantly less concerned about the use of genetic engineering
to treat disease than they are about its use for enhancement or
trait selection.203 In fact, 59% of parents with a child under the
age of 18 said that they would want gene editing to reduce their
baby’s risk of disease, while only 39% of these parents indicated
that they would not.204 As people learn more about the subject, it
is likely that their attitudes will shift in favor of therapeutic
HGM.205
b.
The Proposed Exception is in Line with
Expert Consensus
The proposed exception is generally in line with the
recommendations from the National Academy of Sciences and the
National Academy of Medicine, which were released earlier this
year in the Human Genome Editing Report (the Report).206 The
Report was authored following the conclusion of the 2015
Julie Rovner, Abortion Funding Ban Has Evolved Over The Years, NAT’L
PUBLIC RADIO (Dec. 19, 2009, 6:00 AM),
http://www.npr.org/templates/story/story.php?storyId=121402281.
200 Id.
201 Health and Human Services, and Related Agencies Appropriation Act, 1994,
Pub. L. No. 103-112, 107 Stat. 1082, 1113 (1993).
202 DNC Platform Includes Historic Call to Repeal Anti-Choice Hyde
Amendment, DEMOCRACY NOW! (June 27, 2016),
https://www.democracynow.org/2016/6/27/headlines/dnc_platform_includes_h
istoric_call_to_repeal_anti_choice_hyde_amendment.
203 Funk, supra note 155.
204 Id.
205 See id. (demonstrating that 57% of Americans who are familiar with gene
editing would use it on their own children to reduce the risk of serious disease,
while only 37% of people who know nothing about the subject would opt for the
procedure).
206 NAT’L ACAD. OF SCI. & NAT’L ACAD. OF MED., Human Genome Editing:
Science, Ethics, and Governance – Report Highlights (Feb. 2017), available at
http://nationalacademies.org/cs/groups/genesite/documents/webpage/gene_17
7260.pdf [hereinafter NAT’L ACADEMIES].
199
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International Summit on Human Gene Editing.207 Its authors
include experts in science, medicine, and public policy from
around the world.208 The Report was compiled after an extensive
review of the literature, as well as discussions with clinicians,
researchers, policymakers, and patient advocates, among
others.209 Thus, the Report represents over a year of concerted
effort by a collection of some of the most qualified experts in the
world and their recommendations should be afforded due
consideration.
The two major recommendations with respect to HGM
were (1) to “[p]ermit clinical research trials only for compelling
purposes of treating or preventing serious disease or disabilities,
and only if there is a stringent oversight system able to limit uses
to specified criteria”; and (2) that “[o]ngoing reassessment and
public participation should precede any heritable germline
editing.”210 The committee defined a set of criteria for the clinical
use of HGM in treating disease that closely mirrors the proposed
amendment.211 With respect to genetic enhancement, the
Academies suggested “not [to] proceed at this time with human
genome editing for purposes other than treatment or prevention
of disease and disability.”212 Adoption of the proposed amendment
— or something of similar scope — would ensure that the
committee’s recommendations are respected, and HGM would not
be applied recklessly.
c.
The IOM Report Further Bolsters the
Case for an HGM Exception
Congress may already have to amend the FDA rider to
accommodate recommendations by the Institute of Medicine
(IOM), which suggested that the U.S. move forward with limited
clinical trials for MRT. As the rider has been interpreted to
See Sara Reardon, US science advisers outline path to genetically modified
babies, NATURE (Feb. 14, 2017), available at http://www.nature.com/news/usscience-advisers-outline-path-to-genetically-modified-babies-1.21474.
208 See NAT’L ACADEMIES, supra note 206, at 4.
209 Id. at 1.
210 Id. at 3.
211 The criteria includes, among other things “[1] absence of reasonable
alternatives; [2] restriction to preventing a serious disease or condition; [and]
[3] restriction to editing genes that have been convincingly demonstrated to
cause or strongly predispose to that disease or condition[.]” Id. at 3. Many of
the additional criteria could be achieved by allowing the FDA to put into place
a specialized clinical evaluation process for HGM. See id. at 4.
212 Id.
207
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preclude any clinical evaluation of MRT, Congress may have to
amend the rider if they are to heed the recommendations of the
IOM report.213
In 2016, the IOM provided a report at the request of the
FDA and the National Academies proposing a path forward for
the clinical application of MRT. 214 Acknowledging that the FDA’s
purview extends only to safety and efficacy, the IOM committee
specifically reviewed the “social, ethical and policy”
considerations of MRT.215 They concluded that most of the
concerns about germline modification (1) could be “avoided
through limitations on the use of MRT” or (2) “are blunted by
meaningful differences between the heritable genetic
modification of nDNA and that introduced by MRT.”216
First, the report suggested that only limited applications of
MRT should be evaluated, especially at the early stages of
development.217 In addition to other restrictions,218 the IOM
recommended that the clinical evaluation of MRT should proceed
for clinical trials that involved “transferring only male embryos
for gestation to avoid introducing heritable genetic
modification[.]”219 This is because the mtDNA from the father is
not passed on during procreation,220 which may be caused by
degradation of the mtDNA during fertilization of an oocyte.221
Only the mother’s mtDNA are passed down to the children.222
Because the male children could not pass on the donor’s mtDNA,

See Cohen & Adashi, supra note 80.
Claiborne, supra note 28.
215 See id.
216 Id.
217 Id. at 10.
218 Id. (The IOM also recommended that only pursing studies (1) that “focus on
minimizing the future child’s exposure to risk while ascertaining the safety
and efficacy of the techniques;” and (2) were limited to “women who are
otherwise at risk of transmitting a serious mtDNA disease, where the
mutation’s pathogenicity is undisputed, and the clinical presentation of the
disease is predicted to be severe.”).
219 Id.
220 See Tanya Lewis, Why Paternal Mitochondria Aren’t Passed On to
Offspring, SCIENTIST (Jun. 24, 2016), http://www.thescientist.com/?articles.view/articleNo/46414/title/Why-PaternalMitochondria-Aren-t-Passed-On-to-Offspring/.
221 See Qinghua Zhou, et al., Mitochondrial endonuclease G mediates
breakdown of paternal mitochondria upon fertilization, SCIENCE (Jun. 23,
2016), available at
http://science.sciencemag.org/content/early/2016/06/22/science.aaf4777.full.pd
f+html.
222 See id.
213
214
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the use of MRT to treat male children would not result in a
“heritable genetic mutation.”223
Second, the committee noted that there were “significant
and important distinctions between [the] modification of mtDNA
and nDNA[,]” which affect the ethical, social, and policy
considerations for MRT.224 For example, although “mtDNA plays
a central role in genetic ancestry,” the traits encoded in nDNA
“are those that in the public understanding” are more important
for genetic relatedness . . . and disease.225 Moreover, while
mtDNA may be used for “energetic enhancement” purposes, “they
appear to be far fewer and more speculative relative to [those
enhancements that] might be possible in modifications of
nDNA.”226 Based on these considerations, the committee
“conclude[d] that it is ethically permissible to conduct clinical
investigations of MRT, subject to certain conditions and
principles[.]”227
Yet, clinical development of MRT may be precluded by the
2017 rider.228 The 2017 rider precludes any “a human embryo is
intentionally created or modified to include a heritable genetic
modification.”229 In theory, heritable genetic modifications could
be avoided by only transferring the nuclei from male zygotes.230
Such an approach would be in line with the recommendations of
the IOM report.231 However, a statement from Paul Richards, the
spokesman for the FDA’s Center for Biologics Evaluation and
Research, indicated that the agency deems the current rider to
preclude any “human subject research utilizing genetic
modification of embryos for the prevention of transmission of
mitochondrial disease[.]”232 Thus, it appears that the rider must
be amended before the FDA is willing to act on the IOM Report.233
Claiborne, supra note 28.
Id. at 8.
225 See id. at 8.
226 Id.
227 Id.
228 See Cohen & Adashi, supra note 80.
229 2017 rider, supra note 55.
230 See Anne Claiborne, supra note 28.
231 Id.
232 See Zachary Brennan, Expert Committee: FDA Should Allow Mitochondrial
Replacement Trials Under Certain Conditions, REG. AFFAIRS PRO. SOC. (Feb. 3,
2016),
http://raps.org/Regulatory-Focus/News/2016/02/03/24245/ExpertCommittee-FDA-Should-Allow-Mitochondrial-Replacement-Trials-UnderCertain-Conditions/.
233 It may be possible that the FDA decides to move forward with the use of
MRT in male children without an amendment to the rider. However, MRT will
be eventually be required to treat female children, at which time an
amendment will be necessary.
223
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Without an exception to the 2017 rider, there is no path to
clinical evaluation of MRT in the U.S. As a result, desperate
parents may be forced to undergo the treatment off-shore,
incurring added expense and potential danger. In fact, at least
one such incident has already been reported: on April 6, 2016, the
first baby was born using MRT in Mexico.234 The mother carried
the gene signature for Leigh syndrome, a fatal disorder caused by
mutations in the mitochondrial DNA.235 As MRT is not approved
in the U.S. and might never be under the current language of the
rider, the team of doctors decided to conduct the procedure in
Mexico, where “there are no rules” against the procedure. 236 The
baby boy, now over one year old, was last known to be in good
condition and will be monitored for any safety issues.237 If
changes are not made to the law that accommodate treatment for
select genetic diseases, these incidents are likely to continue in
the future.
The IOM recommendations that allow selected
applications of MRT significantly bolster the argument in favor of
a limited exception that would allow FDA review of selected
therapeutic uses of HGM. First, there is a similar rationale for
the limited use of HGM as there is for the limited use of MRT.
The IOM recommended the use of MRT for women who are
otherwise at risk of transmitting a serious mtDNA disease, where
the mutation’s pathogenicity is undisputed, and the clinical
presentation of the disease is predicted to be severe.238 Similarly,
the proposed exception would allow the use of HGM to treat
“severe or life-threatening genetic diseases with a wellestablished and specific genetic cause, when the end product is a
wild-type gene and its use is restricted to patients who could not
obtain equally effective treatment using other means.”239 The
IOM noted the compelling purpose of MRT: to “satisfy the desire
of a women seeking to have a genetically related child without the
risk of passing on mtDNA disease[s.]”240 The purpose of
therapeutic HGM is nearly identical: it would allow both men and

Jessica Hamzelou, Exclusive: World’s first baby born with new “3 parent”
technique, NEW SCIENTIST (Sept. 27, 2016),
https://www.newscientist.com/article/2107219-exclusive-worlds-first-babyborn-with-new-3-parent-technique/.
235 Id.
236 Id.
237 Id.
238 Claiborne, supra note 28.
239 See proposed amendment, above.
240 Id. at 1.
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women who are afflicted with a genetic disease to have genetically
related children without the risk of passing on nDNA diseases.
Second, the committee’s findings that “distinctions
between modification of mtDNA and nDNA” warrant treatment
of mtDNA diseases but not nDNA diseases are not persuasive.
The report asserts that “the replacement of whole, intact, and
naturally occurring mitochondrial genomes” is significantly
different from approaches using “targeted genomic editing[.]”241
However, some heterogeneity of mtDNA is observed during
MRT,242 and targeted editing that resulted in a wild-type gene
would also result in “naturally occurring” genes.243 In addition,
targeted editing approaches may eventually lead to less genetic
disruption than MRT because they only change parts selected
genes, instead of entire blocs of mtDNA.
The report contends that unlike mtDNA, “traits that are
carried in nDNA are those that in the public understanding
constitute the core of genetic relatedness.”244 However,
therapeutic HGM would only be approved by the FDA if there was
little to no change of off-target editing.245 Thus, any clinicallyacceptable use of HGM should only result in de minimis
alteration of the genome. Those genes on the nDNA that are
associated with the core of genetic relatedness would be left
unaltered by HGM, and the ancestral link between parent and
child would be left intact.
The report also notes that mtDNA is limited in its effect on
the organism and that any opportunities for enhancement using
mtDNA “appear to be far fewer and more speculative relative to
what might be possible in modifications of nDNA.”246 This
distinction is predicated on an assumption that therapeutic HGM
will necessarily lead to enhancement. Yet, the report itself
unambiguously proposes that the MRT ought to be—and can be—
limited to therapeutic purposes.247 The same limitations can and
should be imposed on the use of HGM.
Id. at 8.
Thomas Klopstock, et al., Mitochondrial replacement approaches: challenges
for clinical implementation, 8 GENOME MED. 1 (Nov. 25, 2016), available at
https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-016-03802.
243 By definition, a wild-type gene is a naturally occurring gene.
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245 See generally Cellular & Gene Therapy Guidance, FED. DRUG ADMIN. DEPT.
OF
HEALTH & HUMAN SAFETY (last updated Sept. 6, 2017),
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryI
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Finally, although therapeutic HGM would necessarily
result in “heritable genetic mutations,” this alone is not enough
to override the benefits that safe and effective HGM could offer.
The IOM report indicated that the possibility of such heritable
modifications should not necessarily preclude the use of MRT that
resulted in inheritable mutations.248 The committee proposed
that the FDA could consider extending the use of MRT to female
embryos as long as safety and efficacy were established and the
decision was consistent with public and scientific deliberations on
acceptable limits of applicability.249 If such an approach is
acceptable for the use of MRT, there is no reason why it should
not also be adopted for the therapeutic application of HGM.
d.

Safety and Ethical Considerations

For some afflicted with a severe genetic disease, HGM may
represent the only viable option for having healthy, geneticallyrelated children. Although these people may be relatively few in
numbers, the harm that they suffer is real and their burden is
immense. The current rider prevents them from accessing the one
therapy that could help. It unnecessarily forces them to choose
between rearing a child who will suffer a debilitating disease, or
to forego parenthood in its entirety. Some may choose the latter
option and for those people, the rider is a direct affront to their
reproductive liberty.250 Others may be forced to engage in
reproductive tourism, incurring great cost and health risk for
themselves and their children.
Commentators have claimed that SCE can and will provide
alternative treatments, obviating the need for HGM; however,
SCE is not without its drawbacks. First, SCE can be extremely
expensive: the cost of Glybera, the world’s first gene therapy, is
about one million dollars.251 The treatment is so expensive that it
Id. at 13.
See id. (noting that the FDA “could consider extending . . . MRT to . . . female
embryos if clear evidence of safety and efficacy from male cohorts . . . were
available, . . . preclinical research in animals has shown evidence of
intergenerational safety and efficacy; and FDA’s decisions were consistent with
the outcomes of public and scientific deliberations to establish . . . the
acceptability of and moral limits on heritable genetic modification.”).
250 A constitutional analysis of the impact of the 2017 rider on reproductive
liberty is beyond the scope of this paper. For a general review of this topic, see,
e.g., Carl H. Coleman, Assisted Reproductive Technologies and the
Constitution,
30
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(2002),
http://ir.lawnet.fordham.edu/cgi/viewcontent.cgi?article=1847&context=ulj.
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has only been used commercially for one patient.252 For many
indications, HGM may prove to be a far cheaper and more
effective option. Second, SCE is complicated and can be fraught
with risk. It is well known that the retroviral vectors used to
deliver the gene editing tools for SCE can lead to insertional
mutagenesis, causing unintended genetic mutations in off-target
and on-target cells.253 Side effects of SCE include acute
inflammatory reactions,254 development of cancer,255 and
death.256 While SCE requires genetic manipulation of millions of
cells targeted to a specific organ, HGM requires successful gene
editing only in single-celled zygotes.257 Although SCE is a
promising technology for the treatment of many indications, it
may not be an adequate substitute for HGM in all cases.
The proposed amendment would allow the development of
complementary treatments that could have the potential to save
lives and reduce the debilitating costs of healthcare. Moreover, if
either PGD or SCE were found to be equally efficacious
alternatives, the proposed amendment would preclude the FDA
development of HGM in this field, because the exception is limited
to situations “where the patients could not obtain equally
effective treatment using other means.”258
As previously discussed, the most widely disseminated
ethical opposition to the use of therapeutic HGM is that its use
will start down a slippery slope towards enhancement. Such uses
can continue to be prevented in exactly the same manner as they
currently are: by the precluding FDA review of any application of
HGM for enhancement. The proposed amendment does just that
Id.
See Samantha L. Ginn, et al., Gene therapy clinical trials worldwide to
2012 – and update, 15 J. GENE MED. 65, 68 (2013),
http://onlinelibrary.wiley.com/doi/10.1002/jgm.2698/full;
see also Christopher Baum, Insertional mutagenesis in gene therapy and stem
cell biology, 14 CURR. OPIN. HEMATOL. 337 (Jul. 2007),
http://journals.lww.com/cohematology/pages/articleviewer.aspx?year=2007&issue=07000&article=00006
&type=abstract.
254 See M.J. Kennedy, Current status of gene therapy for cystic fibrosis
pulmonary disease, 1 AM. J. RESPIR. MED. 349 (2002),
https://www.ncbi.nlm.nih.gov/pubmed/14720037.
255 See M.E. Gore, Adverse effects of gene therapy: Gene therapy can cause
leukemia: no shock, mild horror but a probe, 10 GENE THERAPY 4, (2003),
available at http://www.nature.com/gt/journal/v10/n1/full/3301946a.html.
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121, 123 (Feb. 7, 2011),
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by limiting the use of HGM to the “treatment of embryos where
there is a substantial risk that the child will be born with a severe
or life-threatening genetic disease, where the disease has a wellestablished and specific genetic cause.”259 Limitations on the
applications of therapies are ubiquitous in healthcare, including,
for example, the IOM’s proposed limitation on the clinical
development of MRT.260
VII.

CONCLUSION

Unless and until the U.S. adopts a comprehensive
legislative scheme that regulates reproductive HGM, the current
rider should be amended to permit the clinical development of
HGM for a narrow subset of severe monogenic diseases. The
amendment proposed in this paper represents a balanced
approach to HGM policy, reflecting the nuanced safety and ethical
issues that were invoked by the legislature when crafting the
rider in the first place. First, the proposed amendment limits the
application of HGM only to those uses with the most compelling
moral imperative: the treatment of severe genetic diseases.
Second, the proposed amendment maintains the current ban on
the use of HGM for enhancement, which has the highest danger
for misuse. Third, the amendment would only allow the gene
editing that results in wild-type genes, alleviating any concern
about introducing augmented genes into the gene pool. Finally,
careful FDA scrutiny of any HGM protocol should be maintained
throughout the entire process of clinical development, ensuring
that HGM is only used if it is safe and efficacious.
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